Skip to main content
  1. Ethical Science News

  2. Oct 6, 2020

Javelin Biotech and Pfizer Collaborate To Develop Microphysiological System To Predict Human Pharmacokinetics

Study in a Sentence: Javelin Biotech and Pfizer have entered a three-year collaboration to design and build a platform to evaluate absorption, distribution, metabolism, and excretion (ADME) properties of small molecules on an organ-on-a-chip platform to help inform human pharmacokinetic (PK) predictions for new drug candidates in preclinical research. 

Healthy for Humans: Preclinical drug development currently uses animals and in vitro platforms to characterize ADME properties of drug candidates. This advanced ADME platform is a microphysiological system containing the most important human tissues involved in drug disposition (liver, kidney, intestine, and tissue distribution). The system will be paired with a computational algorithm that will translate the data to a physiologically based model of human PK.

Redefining Research: This collaboration has the potential to transform how human PK is evaluated, without dosing humans or using animals. The platform aims to provide a deeper understanding of how drugs perform in humans and supports quantitative decision making to guide first-in-human dosing strategy for Phase I clinical trial design. This technology intends to provide higher confidence in drug candidates that hopefully will lead to breakthroughs to improve human health and save human and animal lives. 


The Science Advisory Board. “Javelin, Pfizer to develop organ-on-a-chip platform.” September 24, 2020. 

More on Ethical Science